Abstract CT130: Evidence for synergistic immune responses in the first-in-human (FIH) combination of B cell-activating immunotherapy (IO) with anti-PD1 immune checkpoint inhibitor nivolumab (N) as 2nd-line therapy in patients (pts) with advanced non-small cell lung cancer (aNSCLC)

2020 ◽  
Author(s):  
Tania Crombet ◽  
Jason Muhitch ◽  
Circe Mesa ◽  
Rachel Evans ◽  
Danay S. Hernandez ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Immune Responses ◽  
Small Cell Lung Cancer ◽  
B Cell ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Line Therapy

scholarly journals Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer

2019 ◽  
Vol 10 (3) ◽  
pp. 526-532 ◽  
Author(s):  
Yuki Katayama ◽  
Tadaaki Yamada ◽  
Keiko Tanimura ◽  
Akihiro Yoshimura ◽  
Takayuki Takeda ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Bowel Movement ◽  
Checkpoint Inhibitor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Movement Condition
Sign in / Sign up

Export Citation Format

Share Document